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ABSTRACT 
Increased airway smooth muscle (ASM) mass is a prominent hallmark of airway remodeling 
in asthma. Inhaled corticosteroids and long-acting beta2-agonists remain the mainstay of 
asthma therapy, however are not curative and ineffective in attenuating airway remodeling. 
The geranyl acetophenone 2,4,6-trihydroxy-3-geranyl acetophenone (tHGA), an in-house 
synthetic non-steroidal compound, attenuates airway hyperresponsiveness and remodeling in 
murine models of asthma. The effect of tHGA upon human ASM proliferation, migration and 
survival in response to growth factors was assessed and its molecular target was determined. 
Following serum starvation and induction with growth factors, proliferation and migration of 
human bronchial smooth muscle cells (hBSMCs) treated with tHGA were significantly 
inhibited without any significant effects upon cell survival. tHGA caused arrest of hBSMC 
proliferation at the G1 phase of the cell cycle with downregulation of cell cycle proteins, cyclin 
D1 and diminished degradation of cyclin-dependent kinase inhibitor (CKI), p27Kip1. The 
inhibitory effect of tHGA was demonstrated to be related to its direct inhibition of AKT 
phosphorylation, as well as inhibition of JNK and STAT3 signal transduction. Our findings 
highlight the anti-remodeling potential of this drug lead in chronic airway disease. 
